Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

TUESDAY, Jan. 7, 2025 (HealthDay News) -- For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a ...

Given the various co-morbidities associated with obesity, including diabetes and cardiovascular disease, intuitively, it would seem that GLP-1 use for weight loss would reduce overall medical ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Multiple studies had already shown that their benefits might go beyond weight loss and diabetes. Those studies showed that patients taking GLP-1 medication fared better against a wide range of health ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

Users of Ozempic and other drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...

Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may ... sleep disturbances and non-infectious gastroenteritis, which is inflammation of the digestive tract which ...